Fri, May 7, 2021

Paul Choi Maintained (BBIO) at Strong Buy with Decreased Target to $80 on, May 7th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-80-on-may-7th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $92 to $80 on, May 7th, 2021.

Paul has made no other calls on BBIO in the last 4 months.



There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Paul


  • Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $75 on, Tuesday, March 23rd, 2021
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $86 on, Thursday, March 4th, 2021
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $87 on, Monday, January 11th, 2021